Similar articles

• A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.

  Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L. Crump M, et al. Leuk Lymphoma. 2010 Feb;51(2):252-60. doi: 10.3109/10428190903585286. Leuk Lymphoma. 2010. PMID: 20109071 Clinical Trial.
• Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.

  Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K. Minami H, et al. Cancer Sci. 2008 Jul;99(7):1492-8. doi: 10.1111/j.1349-7006.2008.00837.x. Epub 2008 May 12. Cancer Sci. 2008. PMID: 18477034 Free PMC article. Clinical Trial.
• Sorafenib (BAY 43-9006): review of clinical development.

  Ng R, Chen EX. Ng R, et al. Curr Clin Pharmacol. 2006 Sep;1(3):223-8. doi: 10.2174/157488406778249325. Curr Clin Pharmacol. 2006. PMID: 18666747 Review.
• Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.

  Hilger RA, Richly H, Grubert M, Kredtke S, Thyssen D, Eberhardt W, Hense J, Schuler M, Scheulen ME. Hilger RA, et al. Int J Clin Pharmacol Ther. 2009 Jan;47(1):61-4. doi: 10.5414/cpp47061. Int J Clin Pharmacol Ther. 2009. PMID: 19203541 No abstract available.
• Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

  Hiles JJ, Kolesar JM. Hiles JJ, et al. Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. doi: 10.2146/ajhp060661. Am J Health Syst Pharm. 2008. PMID: 18192256 Review.